CTCBIO Inc
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergi… Read more
CTCBIO Inc (060590) - Total Liabilities
Latest total liabilities as of September 2025: ₩77.43 Billion KRW
Based on the latest financial reports, CTCBIO Inc (060590) has total liabilities worth ₩77.43 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CTCBIO Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how CTCBIO Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CTCBIO Inc Competitors by Total Liabilities
The table below lists competitors of CTCBIO Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Muthoot Microfin Limited
NSE:MUTHOOTMF
|
India | ₹82.25 Billion |
|
SDI Group plc
PINK:SDIIF
|
USA | $42.38 Million |
|
AS Tallinna Vesi
F:A1T
|
Germany | €215.43 Million |
|
RS Public Company Limited
BK:RS-R
|
Thailand | ฿5.14 Billion |
|
Bank of Botetourt
PINK:BORTP
|
USA | $807.94 Million |
|
Currency Exchange International Corp
PINK:CURN
|
USA | $43.67 Million |
|
Hoang Quan Consulting Trading Service Real Estate Corp
VN:HQC
|
Vietnam | ₫3.51 Trillion |
|
Patriot One Technologies Inc
F:0PL
|
Germany | €10.94 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down CTCBIO Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CTCBIO Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CTCBIO Inc (2011–2024)
The table below shows the annual total liabilities of CTCBIO Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩84.07 Billion | -7.02% |
| 2023-12-31 | ₩90.42 Billion | -1.65% |
| 2022-12-31 | ₩91.94 Billion | +10.48% |
| 2021-12-31 | ₩83.21 Billion | -17.49% |
| 2020-12-31 | ₩100.86 Billion | -9.76% |
| 2019-12-31 | ₩111.76 Billion | +6.62% |
| 2018-12-31 | ₩104.82 Billion | -11.04% |
| 2017-12-31 | ₩117.82 Billion | +20.49% |
| 2016-12-31 | ₩97.78 Billion | +3.50% |
| 2015-12-31 | ₩94.47 Billion | +23.28% |
| 2014-12-31 | ₩76.63 Billion | +31.56% |
| 2013-12-31 | ₩58.25 Billion | -7.49% |
| 2012-12-31 | ₩62.96 Billion | +29.78% |
| 2011-12-31 | ₩48.52 Billion | -- |